Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDl-1 treatment

Andrea Botticelli, Ilaria Zizzari, Federica Mazzuca, Paolo Antonio Ascierto, Lorenza Putignani, Luca Marchetti, Chiara Napoletano, Marianna Nuti, Paolo Marchetti

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Immune Checkpoint Inhibitors (ICIs) are improving the survival of cancer patients, however only the 20-30% of treated patients present clinical benefits. Toxicity represents the major cause of reduced dosage, delayed drug administration and therapy discontinuation. Hence in the context of multiple treatment possibilities, the identification of predictive markers of response and toxicity is a challenging approach for drug selection in order to obtain the best clinical benefit while minimizing the side effects. The loss of the protective function of intestinal barriers that interacts with the environment measured as increased intestinal permeability and the changes occurring in the microbiota composition have been proposed as a mechanism potentially explaining the pathogenesis of immune related toxicity. In this review we discuss the new perspectives on the involvement of PD-1 and PDL-1 in the cross talk between gut microbiota and immune fitness and how gut microbiota impacts on the efficacy of anti-PD-1 and anti-PDL-1 treatments in cancer.

Original languageEnglish
Pages (from-to)8890-8899
Number of pages10
JournalOncotarget
Volume8
Issue number5
Publication statusPublished - Jan 1 2017

Fingerprint

Microbiota
Permeability
Neoplasms
Drug Therapy
Survival
Therapeutics
Pharmaceutical Preparations
Gastrointestinal Microbiome

Keywords

  • CTLA-4
  • Immunotherapy
  • Microbiome
  • PD-1
  • PDL-1

ASJC Scopus subject areas

  • Oncology

Cite this

Botticelli, A., Zizzari, I., Mazzuca, F., Ascierto, P. A., Putignani, L., Marchetti, L., ... Marchetti, P. (2017). Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDl-1 treatment. Oncotarget, 8(5), 8890-8899.

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDl-1 treatment. / Botticelli, Andrea; Zizzari, Ilaria; Mazzuca, Federica; Ascierto, Paolo Antonio; Putignani, Lorenza; Marchetti, Luca; Napoletano, Chiara; Nuti, Marianna; Marchetti, Paolo.

In: Oncotarget, Vol. 8, No. 5, 01.01.2017, p. 8890-8899.

Research output: Contribution to journalReview article

Botticelli, A, Zizzari, I, Mazzuca, F, Ascierto, PA, Putignani, L, Marchetti, L, Napoletano, C, Nuti, M & Marchetti, P 2017, 'Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDl-1 treatment', Oncotarget, vol. 8, no. 5, pp. 8890-8899.
Botticelli A, Zizzari I, Mazzuca F, Ascierto PA, Putignani L, Marchetti L et al. Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDl-1 treatment. Oncotarget. 2017 Jan 1;8(5):8890-8899.
Botticelli, Andrea ; Zizzari, Ilaria ; Mazzuca, Federica ; Ascierto, Paolo Antonio ; Putignani, Lorenza ; Marchetti, Luca ; Napoletano, Chiara ; Nuti, Marianna ; Marchetti, Paolo. / Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDl-1 treatment. In: Oncotarget. 2017 ; Vol. 8, No. 5. pp. 8890-8899.
@article{2d5f0237f665457aa617db0173978cec,
title = "Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDl-1 treatment",
abstract = "Immune Checkpoint Inhibitors (ICIs) are improving the survival of cancer patients, however only the 20-30{\%} of treated patients present clinical benefits. Toxicity represents the major cause of reduced dosage, delayed drug administration and therapy discontinuation. Hence in the context of multiple treatment possibilities, the identification of predictive markers of response and toxicity is a challenging approach for drug selection in order to obtain the best clinical benefit while minimizing the side effects. The loss of the protective function of intestinal barriers that interacts with the environment measured as increased intestinal permeability and the changes occurring in the microbiota composition have been proposed as a mechanism potentially explaining the pathogenesis of immune related toxicity. In this review we discuss the new perspectives on the involvement of PD-1 and PDL-1 in the cross talk between gut microbiota and immune fitness and how gut microbiota impacts on the efficacy of anti-PD-1 and anti-PDL-1 treatments in cancer.",
keywords = "CTLA-4, Immunotherapy, Microbiome, PD-1, PDL-1",
author = "Andrea Botticelli and Ilaria Zizzari and Federica Mazzuca and Ascierto, {Paolo Antonio} and Lorenza Putignani and Luca Marchetti and Chiara Napoletano and Marianna Nuti and Paolo Marchetti",
year = "2017",
month = "1",
day = "1",
language = "English",
volume = "8",
pages = "8890--8899",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "5",

}

TY - JOUR

T1 - Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDl-1 treatment

AU - Botticelli, Andrea

AU - Zizzari, Ilaria

AU - Mazzuca, Federica

AU - Ascierto, Paolo Antonio

AU - Putignani, Lorenza

AU - Marchetti, Luca

AU - Napoletano, Chiara

AU - Nuti, Marianna

AU - Marchetti, Paolo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Immune Checkpoint Inhibitors (ICIs) are improving the survival of cancer patients, however only the 20-30% of treated patients present clinical benefits. Toxicity represents the major cause of reduced dosage, delayed drug administration and therapy discontinuation. Hence in the context of multiple treatment possibilities, the identification of predictive markers of response and toxicity is a challenging approach for drug selection in order to obtain the best clinical benefit while minimizing the side effects. The loss of the protective function of intestinal barriers that interacts with the environment measured as increased intestinal permeability and the changes occurring in the microbiota composition have been proposed as a mechanism potentially explaining the pathogenesis of immune related toxicity. In this review we discuss the new perspectives on the involvement of PD-1 and PDL-1 in the cross talk between gut microbiota and immune fitness and how gut microbiota impacts on the efficacy of anti-PD-1 and anti-PDL-1 treatments in cancer.

AB - Immune Checkpoint Inhibitors (ICIs) are improving the survival of cancer patients, however only the 20-30% of treated patients present clinical benefits. Toxicity represents the major cause of reduced dosage, delayed drug administration and therapy discontinuation. Hence in the context of multiple treatment possibilities, the identification of predictive markers of response and toxicity is a challenging approach for drug selection in order to obtain the best clinical benefit while minimizing the side effects. The loss of the protective function of intestinal barriers that interacts with the environment measured as increased intestinal permeability and the changes occurring in the microbiota composition have been proposed as a mechanism potentially explaining the pathogenesis of immune related toxicity. In this review we discuss the new perspectives on the involvement of PD-1 and PDL-1 in the cross talk between gut microbiota and immune fitness and how gut microbiota impacts on the efficacy of anti-PD-1 and anti-PDL-1 treatments in cancer.

KW - CTLA-4

KW - Immunotherapy

KW - Microbiome

KW - PD-1

KW - PDL-1

UR - http://www.scopus.com/inward/record.url?scp=85016945039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016945039&partnerID=8YFLogxK

M3 - Review article

VL - 8

SP - 8890

EP - 8899

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 5

ER -